-50000 mg/kg [SPX], and 38 -100000 mg/kg [CIP] were performed in a murine aerosol infection model. MXF was the most efficacious agent (3.0 ± 0.2 Log 10 CFU/lung reduction), followed by SPX (1.4 ± 0.1) and OFX (1.5 ± 0.1). CIP showed no effect. fAUC/MIC was the pharmacodynamic parameter that best described the in vivo efficacy.
Introduction
Fluoroquinolones (FQs) exhibit potent in vitro and in vivo antimycobacterial activity (2, 11) .
There is a significant effort to include fluoroquinolones as new front-line agents (OFX and MXF; 17, 27, 30) and second line agents (CIP; 28). There is also considerable effort in the industry to discover and develop newer fluoroquinolones and some of them might have value in the treatment of tuberculosis. However, the choice of the fluoroquinolone for treatment of tuberculosis is dictated by its efficacy in murine models and as a consequence only very few members of the class are tested due to the complexities in the animal models for tuberculosis. Recently, we described an approach to determine the PK/PD driver and its magnitude for efficacy in an aerosol infection model of murine tuberculosis for rifampicin and isoniazid (20, 21) . By applying such a process, it is possible to rationally screen fluoroquinolones that might be otherwise missed because of either the lack of or the inappropriate use of in vitro parameters.
Due to the broad spectrum of activity of fluoroquinolones, it may be possible to extrapolate the findings from studies on Gram negative and Gram-positive organisms in terms of the PK/PD driver and its magnitude required to treat tuberculosis. MFX, which yields the highest fAUC/MIC in standard human doses, is also the most potent fluoroquinolones in a murine model of tuberculosis (16) . However, the size of the fAUC/MIC value achievable in humans, at 70-90, remains well below the optimal value of 100-125, at which the efficacy against gram-negative bacilli is demonstrated (6) . If one were to extrapolate the findings from the Gram-negative pathogens, none of the fluoroquinolones reaches the value of 100-125 as per current dosing regimens (16) . For a Gram-positive pathogen like Streptococcus pneumoniae a fAUC/ MIC of 25-30 was required for efficacy (29) . Thus, it is difficult to predict the pharmacodynamic parameter and its magnitude for efficacy of fluoroquinolones against tuberculosis. An in-depth study of the PK/PD of fluoroquinolones
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on October 16, 2017 by guest http://aac.asm.org/ Downloaded from in a murine model of tuberculosis could not only provide better choice among these agents but may also provide a rational basis for setting the appropriate dose in humans.
In this investigation, we report the PK/PD basis of efficacy for fluoroquinolones against M. tuberculosis in an aerosol infection of tuberculosis in BALB/c mice.
[ H37Rv) at concentrations ranging from 32 mg/L to 0.5 mg/L as described previously (21) for 3 days. Intracellular MIC was defined as the minimal concentration that produces a static effect on the bacilli after 3 days of drug exposure. Intracellular efficacy was measured as Log 10 CFU/mL reduction over the assay period. (table 3) . MXF was the most efficacious (3.2 ± 0.2 Log 10 CFU/lung reduction), followed by OFX (1.5 ± 0.1), SPX (1.4 ± 0.1) and CIP had no effect (figure 5). Of note, a plateau for the effect of MXF was not reached, probably due to toxicity preventing MXF being administered over a wider range of doses. The highest fAUC/MIC achieved was lower than that achieved for OFX and SPX. fAUC/MIC was the primary pharmacodynamic parameter that best described the in vivo efficacy of MXF (r2 = 0.94), OFX (r2 = 0.82), and SPX (r2 = 0.79). Although the fT >MIC (%) showed higher correlations for MXF and SPX the scatter was more in fT >MIC curves than for fAUC/MIC curves (figure 5). fC max /MIC showed a poor correlation for the three fluoroquinolones. 

